Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Nitz U, et al. Among authors: chao c. Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29. Breast Cancer Res Treat. 2017. PMID: 28664507 Free PMC article.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Nitz U, et al. Among authors: chao c. Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8. Breast Cancer Res Treat. 2019. PMID: 30632020 Free PMC article.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y. Iwata H, et al. Among authors: chao c. Breast Cancer Res Treat. 2019 Jan;173(1):123-133. doi: 10.1007/s10549-018-4964-y. Epub 2018 Sep 21. Breast Cancer Res Treat. 2019. PMID: 30242578 Free PMC article. Clinical Trial.
Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.
Yamauchi H, Nakagawa C, Takei H, Chao C, Yoshizawa C, Yagata H, Yoshida A, Hayashi N, Hell S, Nakamura S. Yamauchi H, et al. Among authors: chao c. Clin Breast Cancer. 2014 Jun;14(3):191-7. doi: 10.1016/j.clbc.2013.10.017. Epub 2013 Oct 26. Clin Breast Cancer. 2014. PMID: 24321102 Free article.
The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC, Yau TC, Chan MC, Chan SW, Chan TW, Tsang YY, Wong TT, Chao C, Yoshizawa C, Soong IS, Kwan WH, Kwok CC, Suen JS, Ngan RK, Cheung PS. Leung RC, et al. Among authors: chao c. Clin Breast Cancer. 2016 Oct;16(5):372-378. doi: 10.1016/j.clbc.2016.03.002. Epub 2016 Mar 17. Clin Breast Cancer. 2016. PMID: 27105769 Free article.
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S, Trudeau M, Gandhi S, Warner E, Verma S, Pritchard KI, Petrella T, Hew-Shue M, Chao C, Eisen A. Torres S, et al. Among authors: chao c. Oncologist. 2018 Jul;23(7):768-775. doi: 10.1634/theoncologist.2017-0346. Epub 2018 Jan 25. Oncologist. 2018. PMID: 29371476 Free PMC article.
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
Davidson JA, Cromwell I, Ellard SL, Lohrisch C, Gelmon KA, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu DN, Yoshizawa C, Chao C, Peacock S, Chia SK. Davidson JA, et al. Among authors: chao c. Eur J Cancer. 2013 Jul;49(11):2469-75. doi: 10.1016/j.ejca.2013.03.009. Epub 2013 Apr 20. Eur J Cancer. 2013. PMID: 23611660
Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in Brazil.
Mattar A, Fonseca GR, Romão MBA, Shida JY, de Oliveira VM, Bastos MCS, Bagnoli F, Rinaldi JF, Stiepcich MMÁ, da Silva MALG, Jakubowski DM, Chao C, Oliveira SC, Gebrim LH. Mattar A, et al. Among authors: chao c. JCO Glob Oncol. 2021 Jun;7:1003-1011. doi: 10.1200/GO.20.00609. JCO Glob Oncol. 2021. PMID: 34181482 Free PMC article.
3,034 results